An2 Therapeutics, INC 10-Q quarterly reports

AN2 Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued investment in research and development, progress in clinical trials for epetraborole and AN2-502998, and a strong cash position.

AN2 Therapeutics, Inc. reported a net loss of $9.35 million for Q3 2025, narrowing losses year-over-year, while advancing its Chagas disease and oncology programs.

AN2 Therapeutics reported a significant reduction in net loss and cash burn for Q2 2025, driven by strategic restructuring and the discontinuation of its MAC lung disease program, while advancing its Chagas and oncology pipelines.

AN2 Therapeutics announces Q1 2025 financial results and reports that the truncated Phase 3 portion of the EBO-301 study for epetraborole did not meet its primary endpoint, leading to the discontinuation of its development for treatment-refractory MAC lung disease.

AN2 Therapeutics reports a net loss of $12.7 million for the third quarter of 2024 and announces a restructuring plan including a 50% workforce reduction.

AN2 Therapeutics reports its second quarter 2024 financial results and announces a restructuring plan including a workforce reduction after discontinuing a Phase 2/3 clinical trial for epetraborole.

AN2 Therapeutics reported a net loss of $16.6 million for the first quarter of 2024 and paused enrollment in the Phase 3 portion of its Phase 2/3 clinical trial for epetraborole.